Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,653 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (718)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00316030 | Study of Bexarotene in Patients With Acute Myeloid Leukemia | completed | Phase 1 | 54 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 8, 2016 | clinicaltrials |
| NCT01204164 | Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies(TG02-101) | completed | Phase 1 | 120 | Tragara Pharmaceuticals, Inc.INDUSTRY | 1 | May 6, 2016 | clinicaltrials |
| NCT02337595 | Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation(45RA_NEG_DLI) | completed | Phase 1 / Phase 2 | 30 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Apr 22, 2016 | clinicaltrials |
| NCT01075425 | Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 41 | Virginia Commonwealth UniversityOTHER | 1 | Apr 15, 2016 | clinicaltrials |
| NCT00529360 | Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL | completed | Phase 1 / Phase 2 | 32 | New York Medical CollegeOTHER | 1 | Mar 24, 2016 | clinicaltrials |
| NCT01681537 | Lenalidomide Plus Chemotherapy for AML | completed | Phase 1 | 36 | Massachusetts General HospitalOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01398462 | Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | completed | Phase 1 | 69 | JW PharmaceuticalINDUSTRY | 2 | Mar 8, 2016 | clinicaltrials |
| NCT00850382 | Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 89 | University of UlmOTHER | 2 | Mar 1, 2016 | clinicaltrials |
| NCT01413568 | Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 38 | Polyphor Ltd.INDUSTRY | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01690507 | Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML） | completed | Phase 1 / Phase 2 | 29 | Chinese PLA General HospitalOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT02040506 | A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML | completed | Phase 1 | 19 | Igenica Biotherapeutics, Inc.INDUSTRY | 1 | Feb 23, 2016 | clinicaltrials |
| NCT00892190 | Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome | completed | Phase 1 | 9 | University of PittsburghOTHER | 1 | Feb 10, 2016 | clinicaltrials |
| NCT01795378 | Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation(DNKI-II) | completed | Phase 1 / Phase 2 | 56 | Asan Medical CenterOTHER | 1 | Dec 31, 2015 | clinicaltrials |
| NCT01397799 | Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML) | completed | Phase 1 | 24 | Kinex Pharmaceuticals Inc.INDUSTRY | 1 | Dec 7, 2015 | clinicaltrials |
| NCT00039117 | Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia | completed | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT00459212 | GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT01321346 | A Study Of Panobinostat In Children With Refractory Hematologic Malignancies | completed | Phase 1 | 30 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Nov 24, 2015 | clinicaltrials |
| NCT01314599 | Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome | completed | Phase 1 | 45 | PharmaMarINDUSTRY | 1 | Nov 5, 2015 | clinicaltrials |
| NCT01149408 | Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients | completed | Phase 1 | 3 | University of UtahOTHER | 1 | Oct 7, 2015 | clinicaltrials |
| NCT00111683 | MK0457 in Patients With Leukemia (0457-003) | completed | Phase 1 | 28 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 25, 2015 | clinicaltrials |
| NCT01127009 | Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 3 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT00878722 | Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy | completed | Phase 1 / Phase 2 | 41 | Valerio TherapeuticsINDUSTRY | 3 | Jul 28, 2015 | clinicaltrials |
| NCT01403415 | Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma | completed | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 2 | Jul 10, 2015 | clinicaltrials |
| NCT00608361 | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2015 | clinicaltrials |
| NCT00324220 | A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 66 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jul 1, 2015 | clinicaltrials |
| NCT00175812 | Differentiation Induction in Acute Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 24 | University of BergenOTHER | 1 | Jun 24, 2015 | clinicaltrials |
| NCT00995332 | Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine | completed | Phase 1 / Phase 2 | 36 | University of BergenOTHER | 1 | Jun 24, 2015 | clinicaltrials |
| NCT00990587 | Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | completed | Phase 1 | 20 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT01041443 | 5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01344876 | Phase I Study of OPB-51602 in Patients With Hematologic Malignancies | completed | Phase 1 | 20 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01149915 | Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias | completed | Phase 1 | 40 | Threshold PharmaceuticalsINDUSTRY | 1 | May 7, 2015 | clinicaltrials |
| NCT00991133 | A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL) | completed | Phase 1 | 8 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00217646 | Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2015 | clinicaltrials |
| NCT00383474 | Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT01332786 | Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia | completed | Phase 1 | 27 | University Health Network, TorontoOTHER | 2 | Apr 15, 2015 | clinicaltrials |
| NCT00990054 | Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 1 | 36 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 24, 2015 | clinicaltrials |
| NCT01819558 | Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy(ALLO-WT1) | completed | Phase 1 / Phase 2 | 2 | Institut Paoli-CalmettesOTHER | 1 | Mar 20, 2015 | clinicaltrials |
| NCT01120457 | First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers | completed | Phase 1 | 96 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00343798 | A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies | completed | Phase 1 | 23 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 11, 2015 | clinicaltrials |
| NCT00351975 | Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases | completed | Phase 1 | 56 | National Cancer Institute (NCI)NIH | 3 | Dec 23, 2014 | clinicaltrials |
| NCT01132586 | Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 61 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00283114 | A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | completed | Phase 1 | 82 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00703300 | Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Nov 7, 2014 | clinicaltrials |
| NCT00349596 | A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) | completed | Phase 1 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 15, 2014 | clinicaltrials |
| NCT00858572 | STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders | completed | Phase 1 | 31 | Synta Pharmaceuticals Corp.INDUSTRY | 1 | Sep 18, 2014 | clinicaltrials |
| NCT00964873 | A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia | completed | Phase 1 | 29 | Synta Pharmaceuticals Corp.INDUSTRY | 1 | Sep 18, 2014 | clinicaltrials |
| NCT00742625 | Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 95 | National Cancer Institute (NCI)NIH | 1 | Sep 12, 2014 | clinicaltrials |
| NCT00275080 | Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2014 | clinicaltrials |
| NCT01132573 | Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Jul 17, 2014 | clinicaltrials |
| NCT02182596 | DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML(MYLOFRANCE2) | completed | Phase 1 / Phase 2 | 20 | Acute Leukemia French AssociationOTHER | 1 | Jul 8, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Jun 8, 2016source: clinicaltrials